vs
Side-by-side financial comparison of Gain Therapeutics, Inc. (GANX) and Modular Medical, Inc. (MODD). Click either name above to swap in a different company.
Modular Medical, Inc. is the larger business by last-quarter revenue ($108.0K vs $105.4K, roughly 1.0× Gain Therapeutics, Inc.). Gain Therapeutics, Inc. runs the higher net margin — -4255.7% vs -4878.7%, a 623.0% gap on every dollar of revenue. Modular Medical, Inc. produced more free cash flow last quarter ($-4.5M vs $-6.1M).
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineere...
Varian Medical Systems is an American radiation oncology treatments and software maker based in Palo Alto, California. Their medical devices include linear accelerators (LINACs) and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy, and brachytherapy. The company supplies software for managing cancer clinics, radiotherapy centers, and medical oncology practices. Varian Medical Systems employs more than 7,100 people at manufacturing sites...
GANX vs MODD — Head-to-Head
Income Statement — Q3 FY2024 vs Q3 FY2024
| Metric | | |
|---|---|---|
| Revenue | $105.4K | $108.0K |
| Net Profit | $-4.5M | $-5.3M |
| Gross Margin | — | — |
| Operating Margin | -4230.3% | -4878.7% |
| Net Margin | -4255.7% | -4878.7% |
| Revenue YoY | — | 18498.6% |
| Net Profit YoY | 4.9% | -56.9% |
| EPS (diluted) | $-0.17 | $-0.23 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 24 | $105.4K | — | ||
| Q2 24 | $84.5K | — | ||
| Q1 24 | $115.3K | — | ||
| Q4 23 | — | $108.0K | ||
| Q3 23 | — | $257.0K |
| Q3 24 | $-4.5M | — | ||
| Q2 24 | $-8.1M | — | ||
| Q1 24 | $-4.0M | — | ||
| Q4 23 | — | $-5.3M | ||
| Q3 23 | — | $-4.2M |
| Q3 24 | -4230.3% | — | ||
| Q2 24 | -9680.3% | — | ||
| Q1 24 | -3796.7% | — | ||
| Q4 23 | — | -4878.7% | ||
| Q3 23 | — | -1630.4% |
| Q3 24 | -4255.7% | — | ||
| Q2 24 | -9633.2% | — | ||
| Q1 24 | -3481.4% | — | ||
| Q4 23 | — | -4878.7% | ||
| Q3 23 | — | -1627.6% |
| Q3 24 | $-0.17 | — | ||
| Q2 24 | $-0.42 | — | ||
| Q1 24 | $-0.22 | — | ||
| Q4 23 | — | $-0.23 | ||
| Q3 23 | — | $-0.19 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $12.0M | $2.0M |
| Total DebtLower is stronger | $494.4K | — |
| Stockholders' EquityBook value | $8.9M | $3.8M |
| Total Assets | $14.4M | $6.2M |
| Debt / EquityLower = less leverage | 0.06× | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 24 | $12.0M | — | ||
| Q2 24 | $16.9M | — | ||
| Q1 24 | $12.7M | — | ||
| Q4 23 | — | $2.0M | ||
| Q3 23 | — | $6.3M |
| Q3 24 | $494.4K | — | ||
| Q2 24 | $486.4K | — | ||
| Q1 24 | $507.7K | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — |
| Q3 24 | $8.9M | — | ||
| Q2 24 | $11.8M | — | ||
| Q1 24 | $8.6M | — | ||
| Q4 23 | — | $3.8M | ||
| Q3 23 | — | $7.9M |
| Q3 24 | $14.4M | — | ||
| Q2 24 | $19.2M | — | ||
| Q1 24 | $14.6M | — | ||
| Q4 23 | — | $6.2M | ||
| Q3 23 | — | $10.1M |
| Q3 24 | 0.06× | — | ||
| Q2 24 | 0.04× | — | ||
| Q1 24 | 0.06× | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-6.1M | $-4.0M |
| Free Cash FlowOCF − Capex | $-6.1M | $-4.5M |
| FCF MarginFCF / Revenue | -5764.6% | -4133.3% |
| Capex IntensityCapex / Revenue | 0.0% | 462.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 24 | $-6.1M | — | ||
| Q2 24 | $-5.8M | — | ||
| Q1 24 | $-3.6M | — | ||
| Q4 23 | — | $-4.0M | ||
| Q3 23 | — | $-3.3M |
| Q3 24 | $-6.1M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | $-4.5M | ||
| Q3 23 | — | $-3.6M |
| Q3 24 | -5764.6% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | -4133.3% | ||
| Q3 23 | — | -1409.3% |
| Q3 24 | 0.0% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | 462.0% | ||
| Q3 23 | — | 134.2% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
